AOD 9604 Injection

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of aod 9604 injection in China. Welcome to wholesale bulk high quality aod 9604 injection for sale here from our factory. Good service and reasonable price are available.

Obesity has become a global public health problem. The excessive accumulation of subcutaneous adipose tissue is closely related to metabolic syndrome, cardiovascular diseases, etc. Traditional weight loss drugs often limit their application due to systemic side effects. Therefore, the research and development of drugs targeting local adipose tissue has become a hot topic. AOD 9604 injection, as a new type of anti-obesity polypeptide, acts directly on adipose tissue through subcutaneous injection. Its local pharmacological characteristics provide a new idea for the treatment of obesity.AOD 9604, as an anti-obesity polypeptide targeting subcutaneous adipose tissue, achieves the effect of local fat reduction by activating lipolysis and inhibiting fat production. Its unique molecular structure and pharmacological properties give it potential advantages in the treatment of obesity. However, further studies are still needed to optimize its clinical application, including dosage form improvement, combination therapy strategies and long-term safety assessment. In the future, AOD 9604 is expected to become an important drug in the field of local fat reduction, providing a safer and more effective treatment option for obese patients.

AOD 9604 Powder COA

Certificate of Analysis
Compound name	Aod 9604
Grade	Pharmaceutical grade
CAS No.	221231-10-3
Quantity	35g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202501090056
MFG	Jan 9th 2025
EXP	Jan 8th 2028
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.54%
Loss on drying	≤1.0%	0.42%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.98%
Single impurity	<0.8%	0.52%
Total microbial count	≤750cfu/g	95
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	500ppm
Storage	Store in a sealed, dark, and dry place below -20°C

Molecular Structure

 

AOD The chemical name of 9604 is L-phenylalanine-L-tyrosyl-L-L-leucyl-L-L-arginyl-L-Isoleucyl-L-valinyl-L-Glutamide-L-Cysteinyl-L-arginyl-L-seramide-L-valinyl-L -α -glutamide-glycyryl-L-Seramide-L-cysteinylglycyryl-L (cyclic disulfide bonds are connected at positions 7-14 It has the molecular formula C78H123N23O23S2 and a molecular weight of 1815.1 Da. Its structural features include:

N-terminal tyrosine modification: Enhances affinity with receptors.

Cyclic disulfide bond: Enhances molecular stability and prolongs half-life.

Amino acid sequence specificity: It is highly homologous to the 177-191 amino acids of a certain chemical, but the lipolysis activity has been optimized through chemical modification.

 

 

Activation of fat breakdown (lipolysis)

AOD 9604 promotes fat breakdown through the following pathways:

Activation of the β3-AR signaling pathway: AOD 9604 binds to β3-AR on the adipocyte membrane, activates adenylic acid cyclase (AC), increases the intracellular cyclic adenosine monophosphate (cAMP) level, and thereby activates protein kinase A (PKA). PKA phosphorylates hormone-sensitive lipase (HSL), promoting the hydrolysis of triglycerides into free fatty acids (FFA) and glycerol.

Indirect regulation of adipose triglyceride lipase (ATGL) : AOD 9604 May further enhance lipolysis by up-regulating the expression or activity of ATGL.

 

 

Inhibition of fat production

AOD 9604 inhibits adipogenesis through the following mechanisms:

 

Inhibition of adipocyte differentiation: AOD 9604 can down-regulate the expression of peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/ enhancer binding protein α (C/EBPα), and block the differentiation of preadipocytes into mature adipocytes.

Inhibition of lipid synthase activity: AOD 9604 reduces the activities of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC), and decreases de novo synthesis of fatty acids.

Safety Assessment

Acute toxicity

A single subcutaneous injection of AOD 9604 (50 mg/kg) did not cause death or obvious toxic reactions in mice.

Long-term toxicity

Continuous injection of AOD 9604 (10 mg/kg) for 8 weeks did not cause abnormal liver and kidney functions or fluctuations in blood glucose.

The clinical application potential of AOD 9604

 

Indications for local fat reduction

AOD 9604 is applicable to:

Local fat accumulation in areas such as the abdomen and thighs: By directly injecting into the target area, the fat thickness can be reduced.

Adjuvant therapy after bariatric surgery: Improving postoperative skin laxity and fat residue.

Combined application with other therapies

Combined with exercise: AOD 9604 can enhance exercise-induced lipolysis and improve fat loss efficiency.

Combined with cryolipolysis: By inhibiting fat regeneration, it prolongs the effect of cryolipolysis.

Personalized Treatment plan

Dosage adjustment: Adjust the injection dosage based on the patient's weight and fat distribution.

Rotation of injection sites: Avoid local skin reactions.

AOD 9604 Injection, as an active raw material with weight loss effects, shows multiple potentials in its development prospects. The following is an analysis from aspects such as market demand, research progress, and application expansion:

Market demand potential

The problem of obesity is becoming increasingly serious: The global obesity problem has become a public health challenge. Excessive accumulation of subcutaneous adipose tissue is associated with various diseases. Traditional weight loss drugs are often limited due to systemic side effects. AOD 9604, as a local fat loss drug, can precisely act on adipose tissue and reduce fat accumulation, and is expected to meet the market demand for safe and effective weight loss drugs.

Consumer demand growth: As people pay more attention to health and body management, the demand for weight loss products is constantly increasing. AOD 9604 acts directly on adipose tissue through subcutaneous injection to achieve local fat reduction. This precise mode of action may attract more consumers.

 

Research progress Support

The animal experiments have achieved remarkable results: In the obese mouse model, after daily subcutaneous injection of AOD 9604 (250 μg/kg) for 8 weeks, the body weight of the mice decreased by 12%, the subcutaneous fat mass decreased by 25%, and the weight of epididymal adipose tissue significantly decreased, confirming its effectiveness in fat reduction.

The safety was preliminarily verified: The acute toxicity test showed that a single subcutaneous injection of AOD 9604 (50 mg/kg) did not cause death or obvious toxic reactions in mice; In the long-term toxicity experiment, continuous injection of AOD 9604 (10 mg/kg) for 8 weeks did not cause abnormal liver and kidney functions or fluctuations in blood glucose, providing a safety basis for its further research and application.

 

Application expansion possibilities

Indications for local fat reduction: It is suitable for areas with local fat accumulation such as the abdomen and thighs. By directly injecting into the target area, it reduces fat thickness. It can also be used as an auxiliary treatment after bariatric surgery to improve postoperative skin laxity and fat residue.

Combined application with other therapies: When combined with exercise, it can enhance the lipolysis induced by exercise and improve the efficiency of fat loss. When used in combination with cryolipolysis, it can prolong the effect of cryolipolysis by inhibiting fat regeneration.

 

Industry development trends contribute

Market development of pre-filled automatic syringes: The global market size of pre-filled automatic syringes is expected to continue to grow, which provides a more convenient and safe option for the administration method of AOD 9604 Injection and helps improve patients' medication compliance.

Drug research and development innovation: With the continuous advancement of drug research and development technologies, the research on AOD 9604 May become more in-depth, including aspects such as dosage form optimization and combination medication strategies, to further explore its potential.

1. What is AOD 9604?
AOD 9604 is an artificially synthesized peptide fragment. It is derived from the 176-191 amino acid sequence of human growth hormone (hGH), retaining the fat metabolism activity while eliminating the function of promoting growth. Therefore, it is commonly referred to as the "fat-burning peptide".
2. What are the main effects and uses?
It mainly promotes local or overall fat loss by stimulating fat breakdown and inhibiting fat synthesis. It is commonly used to improve body fat distribution and assist in weight management. In clinical studies, its potential benefits for cartilage repair and metabolic syndrome have also been explored.
3. Is it safe? Are there any side effects?
Studies have shown that it is relatively safe with minor side effects, which may include temporary redness, itching or headache at the injection site. Due to its structure being similar to hGH in some parts, it should not be used for long-term or excessive use without monitoring. Moreover, it is prohibited for pregnant women, those in the lactation period, and patients with severe chronic diseases.
4. How to Use It Properly?
It should be prescription drugs or experimental preparations, and should be used under the guidance of a doctor. Usually, subcutaneous injection is adopted, and the dosage and treatment course need to be individualized. Please obtain the verified products through legal channels and avoid mixing them with unverified drugs.

Hot Tags: aod 9604 injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale